Henan Taloph Pharmaceutical Stock announced that the company participated in the national Chinese Patent Medicine procurement alliance's centralized purchasing bidding work, and the Shuanghuanglian oral liquid and Danshen oral liquid are expected to be selected for this centralized procurement. The expected selection price for the Shuanghuanglian oral liquid is 11.25 yuan/box, and for the Danshen oral liquid is 10.43 yuan/box. The sales revenue for the Shuanghuanglian oral liquid from January to September 2024 is 70.4832 million yuan, accounting for 5.26% of total revenue; the sales revenue for the Danshen oral liquid from January to September 2024 is 41.6637 million yuan, accounting for 3.11% of total revenue. This expected selection is beneficial to promote the access of relevant products to medical terminals and the coverage of sales channels, improving the accessibility of medication for patients.